Literature DB >> 92408

Serum beta 2 microglobulin and its prognostic value in lymphomas.

P L Amlot, M Adinolfi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 92408     DOI： 10.1016/0014-2964(79)90155-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  8 in total

1.  Beta 2-microglobulin in haematological malignancies.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-28

2.  Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.

Authors:  Haizhu Chen; Qiaofeng Zhong; Yu Zhou; Yan Qin; Jianliang Yang; Peng Liu; Xiaohui He; Shengyu Zhou; Changgong Zhang; Lin Gui; Sheng Yang; Liqiang Zhou; Yuankai Shi
Journal:  BMC Cancer       Date:  2022-05-27       Impact factor: 4.638

3.  [Early detection of diabetic nephropathy: serum beta 2-microglobulin].

Authors:  F D Goebel; T Schmeidl; H S Füessl; S Vogel
Journal:  Klin Wochenschr       Date:  1983-12-01

4.  Alteration of serum beta 2-microglobulin in oral carcinoma.

Authors:  C R Wilma Delphine Silvia; D M Vasudevan; K Sudhakar Prabhu
Journal:  Indian J Clin Biochem       Date:  2002-07

5.  Treatment of solid tumors should obligatorily be combined with the in vivo codepletion of tumor-protecting, CD8+/HLA-DR(+)-suppressor T cells by alloreactive donor T cells whose preprogrammed cell death allows a high GvL-effect before GvHD can be established. Results of animal experiments, including more than 6000 mice.

Authors:  P Leskovar; J Bielmeier
Journal:  Pflugers Arch       Date:  1996       Impact factor: 3.657

6.  A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Authors:  Oliver W Press; Joseph M Unger; Lisa M Rimsza; Jonathan W Friedberg; Michael LeBlanc; Myron S Czuczman; Mark Kaminski; Rita M Braziel; Catherine Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker R Dakhil; Thomas P Miller; Richard I Fisher
Journal:  Clin Cancer Res       Date:  2013-10-15       Impact factor: 12.531

7.  Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years.

Authors:  A M Oza; T S Ganesan; M Dorreen; P W Johnson; J Waxman; W Gregory; J Lim; J Wright; L Dadiotis; V Barbounis
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

8.  Estimation of serum β2-microglobulin in potentially malignant disorders and squamous cell carcinoma of the oral cavity: A clinicopathological study.

Authors:  Anand Pratap Singh; Nitin Kumar; Manthena Srinivasa Raju; Narendra Nath Singh; Suma Gundareddy Nagendrareddy
Journal:  Dent Res J (Isfahan)       Date:  2014-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.